Kathleen Mullinix is the CEO and President of WellGen, a company seeking to be the premier expert in nutrigenomics.
Prior to joining WellGen, Mullinix advised investors on biotechnology and pharmaceutical business opportunities with her company Kathleen P. Mullinix & Associates, which she founded in 2002.
Before that, Mullinix served as the founder, chairman, CEO and president of Synaptic Pharmaceutical Corporation. There she led the company from its inception as she developed and implemented the company's strategies for scientific research, business and intellectual property, making it a research-driven public biotechnology company and then an emerging pharmaceutical company.
Before founding Synaptic Pharmaceutical, Mullinix served for six years as vice provost for Columbia University. In this role, she brought Columbia to a leadership position in the commercial development of university intellectual property assets. Additionally, she was instrumental in the development of The Audubon Research Park that has transformed the Columbia Presbyterian Medical Center's Washington Heights neighborhood.
From 1972-1981, Mullinix held two positions with the National Institutes of Health, and served the organization by assisting with strategic matters involving the scientific direction of the NIH intramural program and implementing a novel research program in molecular biology.
Mullinix's comments are from a panel entitled "Exploring Business and Entrepreneurship in Life Sciences" and was hosted by the College of Agriculture and Life Sciences and the Department of Applied Economics and Management at Cornell University in April of 2008. Panelists included Lee Henderson, CEO and Chairman of Vybion, Kathleen Mullinix, CEO and President of WellGen and James Sigler, VP of Business Operations at Air Systems Technologies, Inc.
Kathleen Mullinix holds a Bachelor of Arts degree in Chemistry from Trinity College, a Ph.D. in Chemical Biology from Columbia University and was a National Institutes of Health Postdoctoral Fellow at Harvard University.
In any kind of business there are risks. So pharmaceuticals are just horrible risky, risky, and with this situation our company, yeah, it's very interesting. So where we are is we are hoping that there will be more regulation and more consumer outcry for solid data on natural products around which...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
